Cardiovascular toxicities associated with bispecific T-cell engager therapyAhmed Sayed, Malak Munir, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Meara, Syed Mahmood, Stephanie Feldman, Eric H YangSee the full list of authors
21 February 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong LuoSee the full list of authors
21 February 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-AresSee the full list of authors
12 February 2024
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerShogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Toshihide Ueno, Shinya Kojima, Masashi WakabayashiSee the full list of authors
8 February 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, Michael A Morse, Matthew H Taylor, Katriina J Peltola, Padmanee Sharma, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien, Marina Tschaika, Dung T Le
5 February 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Panagiotis Kourtesis, Maria L Ascierto, Mayukh Das, Jennifer R Diamond, Matthew D Hellmann, Benedito A Carneiro
2 February 2024
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanomaSujin Zhou, Shiwei Zhang, Kexin Zheng, Zixuan Li, Enyu Hu, Yunping Mu, Jialuo Mai, Allan Zhao, Zhenggang Zhao, Fanghong Li
1 February 2024
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLCMarjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels, John Haanen, Jos Beijnen, Arief Lalmohamed
31 January 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, Serigne N Lo, Sheima Farag, Nadia Yousaf, Kate Young, Liselotte Tas, Aafke Meerveld-Eggink, Christian Blank, Austin Thomas, Jennifer McQuade, Bastian Schilling, Douglas B Johnson, Roberto Martín HuertasSee the full list of authors
31 January 2024
Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profileJacob New, Jason Cham, Lana Smith, Leah Puglisi, Tridu Huynh, Sunil Kurian, Samantha Bagsic, Russel Fielding, Lee Hong, Priya Reddy, Ki Suk Eum, Allison Martin, Bethany Barrick, Christopher Marsh, Michael QuigleySee the full list of authors
31 January 2024
